Investigators at the University of Pennsylvania examined the brain of a male donor in his fifties who had undergone 30 administrations of the anti-amyloid medication aducanumab over a span of 4.5 years. The study, published in JAMA and presented at the 2026 Alzheimer’s Association International Conference, highlighted a unique case that demonstrated inconsistent plaque clearance across adjacent brain regions. Areas with reduced amyloid deposits exhibited significantly lower levels of tau, inflammation, and neurodegeneration. These results provide human evidence suggesting that the removal of amyloid could potentially disrupt the advancement of Alzheimer’s disease, although the researchers caution that this single case does not establish a definitive cause-and-effect relationship. Subsequent research will focus on earlier interventions and the responses of specific brain regions.
Disclosure:This video contains stock footage and content created or enhanced using Ai-assisted tools ai-generated
